推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 帝斯曼宣布完成對(duì)江蘇江山制藥的收購(gòu)，此前帝斯曼在2014年7月11日宣布，其已經(jīng)同江蘇江山制藥集團(tuán)達(dá)成收購(gòu)協(xié)議，但此時(shí)不會(huì)公布財(cái)務(wù)數(shù)據(jù)，根據(jù)慣例，交易可能在6—9個(gè)月之內(nèi)完成。
目前，全球市場(chǎng)需求量約為12萬(wàn)噸，主要供應(yīng)商有6家，除DSM蘇格蘭廠外，其余5家均在我國(guó)，分別是石家莊制藥、東北制藥、華藥維爾康、及江山制藥以及魯維制藥。而到目前為止，我國(guó)這5家生產(chǎn)企業(yè)的產(chǎn)能就已經(jīng)與全球VC市場(chǎng)需求量持平。在2014年7月份公布收購(gòu)遠(yuǎn)時(shí)帝斯曼稱，收購(gòu)江山制藥可以更好的滿足DSM財(cái)務(wù)和戰(zhàn)略需求。將會(huì)加強(qiáng)其在維生素C生產(chǎn)領(lǐng)域的地位，維生素C是全球用量最大的維生素。DSM目前在蘇格蘭運(yùn)營(yíng)維生素C生產(chǎn)工廠，江山制藥同樣會(huì)改善DSM維生素業(yè)務(wù)版塊的全球布局，并提高維生素C產(chǎn)能。
據(jù)生意社維生素C商品指數(shù)顯示，4月6日維生素C商品指數(shù)為86.67，較周期內(nèi)最高點(diǎn)106.30點(diǎn)(2014-06-26)下降了18.47%，較2013年04月23日最低點(diǎn)81.98點(diǎn)上漲了5.72%。(注：周期指2012-03-01至今
